The field of psychedelic medicine stands on the cusp of a decisive break from conventional psychiatric treatment models. Once marginalised by politics and prohibition, psychedelic compounds such as psilocybin, MDMA, LSD, DMT, ibogaine and other psychoactive substances are now being rigorously investigated within clinical trials and neuroscientific frameworks to assess their therapeutic potential.
Mounting evidence from controlled trials and translational studies reveals their capacity to treat a range of mental health conditions, including depression, post-traumatic stress disorder (PTSD), addiction, and existential distress, with remarkable efficacy and durability[1]. To date there have been two positive phase III read outs from psychedelic clinical trials, namely MDMA-Assisted Therapy for PTSD and Psilocybin Therapy for Treatment Resistant Depression from Lykos Therapeutics and Compass Pathways respectively[2],[3].
Beyond these positive readouts, there is signal from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory Agency (MHRA) and other major Western medical regulatory agencies that data from such trials will be reviewed in the next 12–24 months with strategies now underway to deliver the future of psychedelic medicine in public and private healthcare settings. This transformation carries significant implications for the healthcare sector at large, but it also heralds a new frontier for insurance.
I see a crucial opportunity for the insurance sector to not merely react to the psychedelic renaissance, but to have a role in shaping it. Ultimately with the end goal of providing access to patients that would otherwise be unable to afford access.
Psychedelic medicine is a fast-evolving, evidence-based clinical movement with over 150 clinical studies and trials now in place globally investigating a variety of these compounds, predominantly in neuropsychiatric disorders such as depression and addiction but increasingly further afield in neurological conditions such as Parkinson’s, Alzheimer’s disease and stroke. Its commercial potential is substantial, its risks complex but navigable, and its long-term societal benefits potentially far-reaching.
What is urgently needed is a health and scientifically focussed- insurance strategy; one that embraces the complexity of delivering a model that requires a more intensive allocation of resources upfront, but a briefer and less resource intensive follow up period as with other psychiatric interventions.
Below, I unpack the current state of the field, delineate the specific risks and unknowns it presents, and argue that forward-looking insurers must position themselves not just as providers of risk transfer, but also as architects of sustainable progress in the emerging psychedelic and alternative therapeutic sector.
Psychedelics are serotonergic compounds that act primarily via the 5-HT2A receptor in the brain, which plays a central role in modulating cortical activity, perception, cognition, and emotional processing.
Recent advances in functional neuroimaging have helped elucidate the mechanisms of action of these compounds. For example, psilocybin changes the integrity of the default mode network (DMN) activity, which is often dysregulated in depressive disorders, addiction and rumination. The disruption of this brain circuit appears to lead to neural changes that perturbate the brain, potentially allowing for the adaptive rewiring of circuits involved in psychiatric disorders.
These neuroscientific investigations have found that psychedelic therapy disrupts such pathological brain states and has the potential to ‘reset’ the brain from pathological or disordered stated to adaptive and healthier states after one or two sessions with psychological support and/or psychological therapy.
Clinical data emerging from clinical trials which started at research centres like at Imperial College London and other biotechnology companies support these mechanistic insights. Randomised Controlled Trials (RCTs) have demonstrated that psilocybin-assisted therapy produces large effect sizes in treatment resistant, major depressive disorder, alcohol use disorder and many other neuropsychiatric conditions, often after just one or two high-dose sessions.
In a 2021 study published in The New England Journal of Medicine, psilocybin was found to be at least as effective as a leading SSRI antidepressant over a six-week period, with fewer side effects and a more rapid onset of action4. More recently Compass Pathways have demonstrated in a Phase III clinical trial that psilocybin therapy is safe and has significantly greater efficacy than placebo in a single-high dose study with psychological support in treatment resistant depression5.
Since then, COMPASS Pathways has reported positive results from both pivotal Phase III trials of COMP360 psilocybin therapy in treatment-resistant depression, while the Trump administration has moved psychedelics further into mainstream regulatory infrastructure through an executive order directing accelerated FDA review pathways, rapid rescheduling following approval, and at least $50 million in federal support for psychedelic research. The FDA has since issued Commissioner’s National Priority Vouchers to several leading psychedelic programmes, including COMP360 psilocybin therapy from COMPASS Pathways, Usona Institute’s psilocybin programme for major depressive disorder, and Transcend Therapeutics’ methylone-based treatment for PTSD.
Importantly, this regulatory momentum is now being mirrored by large-scale pharmaceutical investment into next-generation neuropsychiatric and psychedelic-adjacent therapeutics. AbbVie recently announced a deal worth up to $1.2 billion for Gilgamesh Pharmaceuticals’ psychedelic-inspired 5-HT2A agonist bretisilocin (GM-2505) for depression.
Meanwhile, Otsuka Pharmaceutical acquired methylone developer Transcend Therapeutics in a deal worth up to $1.225 billion ($700 million upfront with up to $525 million in milestone payments), marking one of the largest acquisitions yet involving a psychedelic-derived neuroplasticity platform.
Together, these developments suggest that psychedelic and neuroplasticity-based therapeutics are increasingly being viewed not as fringe interventions, but as strategically important assets within mainstream psychiatry, biotech and pharmaceutical development.
Despite trials still ongoing, several jurisdictions now legally permit early access to psilocybin therapy under various regulatory schemes, these include; Germany, Czech Republic, New Zealand, Canada, Australia, New Zealand and Switzerland with a host of other countries including the US, and areas across Latin, South America, some areas of the Caribbean and the Netherlands allowing for access to these compounds for recreational/spiritual and wellness related means.
Moving beyond Psilocybin, and a step ahead, other compounds including MDMA have also been submitted to regulators for review for their potential therapeutic effects. Other compounds, including ketamine, ibogaine, LSD DMT, derivatives of DMT and second and third generation psychedelic compounds are also being investigated for depression, chronic pain, OCD, anxiety, eating disorders, substance and behavioural addiction disorders and existential distress in palliative care. While the precise mechanisms vary, a unifying theme is the capacity of these substances to induce a temporary disintegration of rigid neural networks, facilitating emotional release, cognitive reframing, and longer-term adaptive psychological change6,7.
These findings challenge conventional models of psychiatric treatment, which often rely on daily pharmacological symptom suppression and/or some form of talking therapy. Psychedelic therapy, by contrast, offers the possibility of deep therapeutic transformation through structured, time-limited interventions, paving the way for the birth of a new treatment modality ‘interventional psychiatry’. In this sense, alternative therapeutics are not merely another option in the treatment toolkit they represent a philosophical and economic challenge to the very foundations of how psychiatric healthcare is delivered, funded and measured.
The psychedelic therapeutics market is projected to exceed $8 billion globally by 2030, growing at a CAGR of 12–15% as regulatory approvals expand and clinical adoption accelerates11. This surge is being driven by high-value indications such as depression, PTSD, and addiction, alongside capital inflows from pharma, with a recent $1.2 billion M&A driven by Abbvie, institutional investors including larger hedge funds and private equity.
Alongside the economic promise provided by this research comes a host of clinical, ethical, legal, and financial uncertainties, ones that insurers must be prepared to help address as a trusted partner of this emerging sector.
For insurers, the opportunity lies in backing evidence-based, high-impact interventions and ancillary organisations that support growth and delivery across the sector. However, with rapid growth comes operational, regulatory and reputational risks that must be managed and mitigated from the outset.
The growth and mainstreaming of psychedelic medicine present a complex risk landscape. This is not simply because the substances are novel (many have been known for decades and centuries) but because their application in traditional medical and healthcare settings blur traditional boundaries between psychiatry, psychology, legal frameworks, public health and consumer goods, as well as the obvious illicit and grey zone market.
Key risk domains include:
Professional risk
Psychedelic therapy requires a hybrid skillset encompassing skills from clinical psychiatry, psychotherapy, trauma-informed care and in some cases spiritual counselling. Yet regulation and training standards remain fragmented across jurisdictions with no approved frameworks yet in place but several courses available. Allegations of malpractice may arise from inadequate screening, poor integration practices or psychological harms that emerge post-treatment and hence this is an important area to engage. The nuanced risks posed by different treatment sites – from hospitals to retreats – need to be considered. Unlike conventional pharmacotherapies, psychedelic therapy currently requires close therapeutic support before, during, and after dosing. Patients may undergo intense emotional experiences, revisit traumatic memories, or enter dissociative states. Failure to provide adequate psychological support, integration, or crisis response could result in harm and claims. Hence, appropriate oversight and risk management related to the delivery of care is critical.
Product risk
With a growing number of biotech companies developing proprietary psychedelic compounds, new questions arise around manufacturing processes and quality control, off-label use, adverse drug reactions and liability arising therefrom.
Regulatory risk
Psychedelic drug legality differs widely across countries and even within countries. Some jurisdictions now permit licensed therapeutic use or personal use; others continue to classify these compounds as Schedule I substances. This regulatory inconsistency can create adverse conditions for investors, disruption in the supply chain, and uncertainty for the financial institutions who are serving the industry and who may be concerned about violations of Proceeds of Crime statutes. .
Reputational risk
The cultural and political history of psychedelics means the sector is vulnerable to intense public scrutiny. The “moral hazard” long associated with alternative therapeutics acts as an appetite suppressant for potential supply chain partners – though it appears these outlooks are slowly shifting. A single high-profile incident, such as an adverse event at a licensed clinic or a misleading wellness claim could damage the reputation of the entire industry and those insuring it. Workig with companies and individuals who have a high degree of clinical fidelity and expertise is paramount.
These risks are real but they are not insurmountable. Many are manageable with governance frameworks, controls and risk transfer (insurance), grounded in the science and ethics of psychedelic care.
The role of insurance in shaping a responsible psychedelic industry
The era of psychedelic medicine has now arrived and is predicted to be key player in the future of mental health treatment and economic growth, but its success is not guaranteed. Without proper safeguards, ethical standards and economic, political and regulatory scaffolding, the sector risks overextension, backlash or harm to vulnerable patients. The insurance sector has a vital role to play in preventing this outcome.
This can be done by:
Psychedelic medicine points to the need for a dedicated suite of insurance products. Crucially, these products must be dynamic and responsive to the needs of this emerging sector. As evidence grows and regulatory frameworks shift, underwriting must be guided by real-world data, expert consensus, and a commitment to patient safety.
That means partnering with researchers, regulators, and clinicians to understand (and develop) shared safety standards, training benchmarks, and treatment protocols.
This article was created in partnership with Relm.
[1] Mitchell, J.M., Anderson, B.T. Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacol. 49, 96–103 (2024). https://doi.org/10.1038/s41386-023-01656-7
